NCT00569127 2026-03-18
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
12 trialsNCT03375320 2026-03-18
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT02246127 2025-05-11
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Completed
NCT03136328 2023-05-09
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Montefiore Medical Center
Phase 3 Completed
NCT03673943 2022-12-22
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
Radiomedix, Inc.
Phase 3 Completed
NCT00774930 2022-10-14
ELECT
Ipsen
Phase 3 Completed
NCT00842348 2022-10-12
NET729
Ipsen
Phase 3 Completed
NCT02683941 2022-07-06
SPINET
Ipsen
Phase 3 Terminated
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT01524783 2021-08-05
RADIANT-4
Novartis
Phase 3 Completed
NCT00171873 2020-03-26
Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Philipps University Marburg
Phase 3 Completed